Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The trial has initially started in Finland, where Adial previously announced it had received approval to commence the trial. The trial is also expected to be conducted in Sweden, Poland, Latvia, Estonia, Croatia, and Bulgaria. Adial has filed clinical trial applications (CTAs) to also conduct the trial in each of these countries where additional trial sites will be initiated on a country-by-country basis following each CTA approval.
We are looking for a new colleague to strengthen our […]
Haemme lääketieteelliseen kielipalvelutiimiimme kääntäjää, jonka äidinkieli on ruotsi. Pääasialliset työkielemme […]
Celebrating Easter during a pandemic is certainly hard for us […]
Pharma Industry Finland recently reported that the pharmaceutical industry invested […]
Study nurse training – introducing a nationwide, fully web-based program (Crown CRO is proud to participate)
The first nationwide study nurse training program (worth four academic […]